Variables | Overall survival (OS) | Progression-free survival (PFS) | Locoregional recurrence-free survival (LRFFS) | Distant metastasis-free survival (DMFS) | ||||
---|---|---|---|---|---|---|---|---|
HR (95% CI)a | P value | HR (95% CI)a | P value | HR (95% CI)a | P value | HR (95% CI)a | P value | |
Age | ||||||||
 ≤ 60 |  |  |  |  |  |  | Ref |  |
 > 60 |  |  |  |  |  |  | 2.510 (1.376–4.580) | 0.003 |
Primary tumor site | ||||||||
 Pyriform sinus | Ref |  | Ref |  | Ref |  | Ref |  |
 Posterior wall/postcricoid | 2.590 (1.252–5.358) | 0.010 | 2.328 (1.224–4.426) | 0.010 | 2.608 (1.163–5.851) | 0.020 | 2.914 (1.296–6.553) | 0.010 |
pT classificationb | ||||||||
 T1–T2 |  |  | Ref |  | Ref |  |  |  |
 T3–T4 |  |  | 1.842 (1.115–3.042) | 0.005 | 3.063 (1.559–6.015) | 0.001 |  |  |
pN classificationb | ||||||||
 N0 |  |  |  |  |  |  | Ref |  |
 N1–N3 |  |  |  |  |  |  | 2.519 (0.335–18.963) | 0.370 |
pTNM stagingb | ||||||||
 I–II |  |  |  |  |  |  | Ref |  |
 III–IV |  |  |  |  |  |  | 1.126 (0.151–8.402) | 0.908 |
No. of metastatic LN | ||||||||
 ≤ 3 |  |  |  |  |  |  | Ref |  |
 > 3 |  |  |  |  |  |  | 1.497 (0.731–3.066) | 0.269 |
LND | ||||||||
 ≤ 0.06 | Ref |  | Ref |  |  |  | Ref |  |
 > 0.06 | 1.959 (0.959–2.974) | 0.070 | 1.971 (1.201–3.237) | 0.007 |  |  | 2.430 (1.206–4.896) | 0.013 |
ECS of LN | ||||||||
 Negative | Ref |  |  |  |  |  | Ref |  |
 Positive | 1.670 (0.866–3.222) | 0.126 |  |  |  |  | 1.326 (0.665–2.647) | 0.423 |
Surgical margin | ||||||||
 Negative | Ref |  | Ref |  | Ref |  |  |  |
 Positive | 2.842 (1.080–7.482) | 0.034 | 1.790 (0.767–4.179) | 0.178 | 3.455 (1.253–9.526) | 0.017 |  |  |
PNI | ||||||||
 > 52.0 | Ref |  | Ref |  | Ref |  | Ref |  |
 ≤ 52.0 | 3.842 (1.963–7.518) | 0.000 | 2.401 (1.419–4.061) | 0.001 | 2.958 (1.388–6.307) | 0.005 | 2.133 (1.154–3.943) | 0.016 |